Crystalline EP4 Antagonist Salt for Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing EP4 antagonists face challenges in terms of chemical and physical stability, making them difficult to manufacture and store effectively as active pharmaceutical ingredients.
Innovation Solution
The development of a crystalline free acid form of a compound according to Formula II, which exhibits specific X-ray powder diffraction peaks and is characterized by a differential scanning calorimetry thermograph, enhancing its stability and storage capabilities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If EP4 antagonists are used as active pharmaceutical ingredients, then pharmaceutical efficacy is achieved, but chemical and physical stability deteriorates
Solution Approach 1:
The patent changes the physical state parameter of the EP4 antagonist from amorphous to crystalline form. This phase transition improves chemical and physical stability while maintaining pharmaceutical efficacy, as crystalline structures have more ordered molecular arrangements that resist degradation pathways.
Solution Approach 2:
The patent utilizes phase transition from amorphous to crystalline state to enhance stability. The crystalline form exhibits improved stability characteristics compared to the amorphous form, allowing the compound to maintain its pharmacological activity while being more resistant to chemical degradation and storage-related changes.
2Duration of action of stationary object
If EP4 antagonists are stored over long periods, then storage capability is improved, but physio-chemical characteristics change significantly
Solution Approach 1:
The patent changes the physical state parameter to crystalline form, which has superior storage stability. The crystalline structure maintains consistent physio-chemical characteristics over extended storage periods, preventing degradation and maintaining pharmacological activity throughout the shelf life of the pharmaceutical product.
Solution Approach 2:
The crystalline form provides beforehand protection against chemical degradation and physical changes during storage. The ordered molecular structure in crystalline form creates a more stable configuration that resists spontaneous degradation pathways, cushioning the compound against environmental factors during long-term storage.
3Stability of the object's composition
If crystalline form is achieved, then stability is improved, but manufacturing complexity increases
Solution Approach 1:
The patent employs parameter changes in the crystallization process, utilizing controlled cooling and pH adjustment to induce crystalline form formation. These parameter modifications are implemented through standard pharmaceutical manufacturing techniques, achieving enhanced stability without requiring complex or proprietary manufacturing equipment.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystalline free acid form of the compound demonstrates improved chemical and physical stability, allowing for effective long-term storage and maintaining its pharmaceutical efficacy.
Implementation Method 1
gives peaks in an X-ray powder diffraction (XRPD) spectra of at least one, two, three, four, five, six or more of the following value ranges of 20° (±0.2°)
Implementation Method 2
characterized by a differential scanning calorimetry (DSC) thermograph substantially the same as shown in FIG. 2
Data Source
AI summary
A crystalline free acid form of (S)-4-(1-(3-(difluoromethyl)-1-methyl-5-(3-(trifluoromethyl)phenoxy)-1H-pyrazole-4-carboxamido)ethyl)benzoic acid is provided. Methods of making and using the crystalline free acid form of (S)-4-(1-(3-(difluoromethyl)-1-methyl-5-(3-(trifluoromethyl)phenoxy)-1H-pyrazole-4-carboxamido)ethyl)benzoic acid are also provided.